Sign In
Buy AZN
$183.02
+2.00 (+1.10%)
At Close: Jun 24, 2026
4 Ideal Barron's Mid-Year 2023 Dividend Dog Buys
07:54am, Sunday, 23'rd Jul 2023
Barron's Mid-Year Roundtable, Published July 17, listed 40 stocks of note for 2023; 38 of those were unduplicated US publicly-listed companies, of-which YCharts reported 25 as paying dividends. Barron
AstraZeneca earnings update comes with shares regrouping after big tumble from peak
12:58pm, Friday, 21'st Jul 2023
In April, AstraZeneca PLC (LSE:AZN) hit an all-time high above £122 per share, topping former suitor Pfizer, before retreating sharply. It has been on the front foot in the weeks leading up to next
Ford EV price cuts, Tesla exec compensation settlement, FDA-approved RSV vaccine: July 17, 2023
06:45pm, Monday, 17'th Jul 2023
Yahoo Finance Akiko Fujita reports the top stories for Monday July 17, 2023 including Ford cutting the price on the F-150 Lightning, Tesla directors settling a compensation lawsuit, and the FDA approv
FDA Approves Antibody For RSV After Challenging 2022 Season
01:32pm, Monday, 17'th Jul 2023
RSV in infants often leads to the development of pneumonia or bronchiolitis—conditions that can result in emergency visits.
FDA Approves First RSV Drug to Protect All Infants
01:13pm, Monday, 17'th Jul 2023
While the virus often leads to mild, coldlike symptoms, it is the leading cause of hospitalization of infants in the U.S.
FDA approves AstraZeneca, Sanofi shot that protects infants and toddlers against RSV
01:12pm, Monday, 17'th Jul 2023US FDA approves Sanofi-AstraZeneca's preventive RSV therapy for babies
01:07pm, Monday, 17'th Jul 2023
U.S. Food and Drug Administration said on Monday it had approved Sanofi and partner AstraZeneca's antibody therapy to prevent respiratory syncytial virus (RSV) in infants and toddlers.
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high
AstraZeneca PLC (AZN) Is a Trending Stock: Facts to Know Before Betting on It
10:17am, Tuesday, 11'th Jul 2023
Astrazeneca (AZN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Here's Why Astrazeneca (AZN) is a Strong Value Stock
10:53am, Friday, 07'th Jul 2023
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
AstraZeneca (AZN) Down 9% on Mixed Lung Cancer Study Results
12:15pm, Tuesday, 04'th Jul 2023
While AstraZeneca's (AZN) late-stage study evaluating an experimental lung cancer treatment showed improvement in progression free survival, it did not meet the threshold for statistical significance
AstraZeneca rebounds as analysts mull 'hard to read' cancer drug update
09:21am, Tuesday, 04'th Jul 2023
Following AstraZeneca PLC's (LSE:AZN) update on its new cancer drug, datopotamab deruxtecan (Dato-DXd), several brokers have weighed in, including Deutsche Bank downgrading its stance and UBS sayin
Biopharma Stock Gaps Lower After Trial Disappoints
10:53am, Monday, 03'rd Jul 2023
AstraZeneca PLC (NASDAQ:AZN) is gapping lower today, after the biopharmaceutical name's lung cancer drug disappointed investors in a late-stage trial.
AstraZeneca Plummets, Sacrificing A Breakout, On Mixed Results In Lung Cancer Treatment
09:17am, Monday, 03'rd Jul 2023
AstraZeneca and Daiichi Sankyo reported mixed results Monday from a final-phase study of their lung cancer treatment, and AZN stock tumbled.
AstraZeneca shares slump after Phase 3 lung cancer drug study
05:36am, Monday, 03'rd Jul 2023
AstraZeneca's AZN, +1.02% AZN, -5.43% shares slumped 6% in premarket trade. The U.K. drugmaker said its datopotamab deruxtecan treatment showed positive results in patients with advanced non-small cel
